Neuropace Inc
NASDAQ:NPCE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.25
18.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Neuropace Inc
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
Record Revenue: NeuroPace posted record Q3 revenue of $27.4 million, up 30% year-over-year, driven mainly by strong RNS system sales.
Profitability Milestone: The company achieved positive adjusted EBITDA for the first time in its history, reflecting improved operating leverage and disciplined expense management.
Raised Guidance: Full-year revenue guidance was raised to $97–98 million and gross margin guidance to 76–77%, both up from prior ranges.
RNS System Strength: RNS revenue grew 31% year-over-year to $22.6 million, with broad-based growth across geographies and accounts.
DIXI Wind-Down: DIXI product revenues are being wound down, with most sales expected to be complete by end of 2025, shifting focus entirely to RNS.
Clinical Progress: PMA submission for the NAUTILUS indication (IGE) remains on track for year-end 2025, targeting potential approval mid-2026; pediatric indication timeline has extended beyond 2025.
AI & Data Initiatives: Submitted the first proprietary AI-enabled EEG software tool (Seizure ID) to the FDA, with more AI applications planned.
Strong Operating Leverage: Operating expense growth (21%) was well below revenue growth (30%), supporting margin expansion.
